Evoke Pharma Stock Operating Margin

EVOK Stock  USD 0.45  0  0.22%   
Evoke Pharma fundamentals help investors to digest information that contributes to Evoke Pharma's financial success or failures. It also enables traders to predict the movement of Evoke Stock. The fundamental analysis module provides a way to measure Evoke Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Evoke Pharma stock.
Last ReportedProjected for Next Year
Operating Profit Margin(1.43)(1.51)
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Evoke Pharma Company Operating Margin Analysis

Evoke Pharma's Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.

Operating Margin

 = 

Operating Income

Revenue

X

100

More About Operating Margin | All Equity Analysis

Current Evoke Pharma Operating Margin

    
  (1.13) %  
Most of Evoke Pharma's fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Evoke Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Evoke Operating Margin Driver Correlations

Understanding the fundamental principles of building solid financial models for Evoke Pharma is extremely important. It helps to project a fair market value of Evoke Stock properly, considering its historical fundamentals such as Operating Margin. Since Evoke Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Evoke Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Evoke Pharma's interrelated accounts and indicators.
0.9-0.83-0.110.38-0.621.00.110.17-0.140.140.01-0.070.110.110.17-0.03-0.140.1
0.9-0.82-0.240.6-0.880.90.320.3-0.380.420.2-0.240.050.210.10.05-0.030.05
-0.83-0.82-0.28-0.240.57-0.83-0.110.19-0.110.080.260.370.340.04-0.08-0.19-0.350.32
-0.11-0.24-0.28-0.480.42-0.11-0.43-0.670.8-0.82-0.94-0.28-0.76-0.51-0.050.260.82-0.74
0.380.6-0.24-0.48-0.730.390.290.34-0.770.790.4-0.030.11-0.09-0.24-0.15-0.10.14
-0.62-0.880.570.42-0.73-0.62-0.43-0.380.58-0.63-0.360.19-0.1-0.24-0.03-0.010.0-0.07
1.00.9-0.83-0.110.39-0.620.110.17-0.150.140.01-0.080.110.120.18-0.03-0.140.09
0.110.32-0.11-0.430.29-0.430.110.38-0.60.550.55-0.47-0.040.36-0.160.74-0.26-0.18
0.170.30.19-0.670.34-0.380.170.38-0.570.60.690.070.470.47-0.09-0.04-0.580.49
-0.14-0.38-0.110.8-0.770.58-0.15-0.6-0.57-0.95-0.760.12-0.32-0.270.16-0.020.51-0.3
0.140.420.08-0.820.79-0.630.140.550.6-0.950.81-0.090.390.35-0.08-0.05-0.470.41
0.010.20.26-0.940.4-0.360.010.550.69-0.760.810.140.610.53-0.07-0.09-0.740.64
-0.07-0.240.37-0.28-0.030.19-0.08-0.470.070.12-0.090.140.6-0.3-0.16-0.67-0.360.58
0.110.050.34-0.760.11-0.10.11-0.040.47-0.320.390.610.60.530.43-0.51-0.830.94
0.110.210.04-0.51-0.09-0.240.120.360.47-0.270.350.53-0.30.530.70.08-0.50.5
0.170.1-0.08-0.05-0.24-0.030.18-0.16-0.090.16-0.08-0.07-0.160.430.7-0.14-0.190.37
-0.030.05-0.190.26-0.15-0.01-0.030.74-0.04-0.02-0.05-0.09-0.67-0.510.08-0.140.22-0.66
-0.14-0.03-0.350.82-0.10.0-0.14-0.26-0.580.51-0.47-0.74-0.36-0.83-0.5-0.190.22-0.78
0.10.050.32-0.740.14-0.070.09-0.180.49-0.30.410.640.580.940.50.37-0.66-0.78
Click cells to compare fundamentals
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
Competition

Evoke Pretax Profit Margin

Pretax Profit Margin

(1.58)

At this time, Evoke Pharma's Pretax Profit Margin is quite stable compared to the past year.
Based on the recorded statements, Evoke Pharma has an Operating Margin of -1.1265%. This is 96.79% lower than that of the Pharmaceuticals sector and significantly lower than that of the Health Care industry. The operating margin for all United States stocks is 79.56% lower than that of the firm.

Evoke Operating Margin Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Evoke Pharma's direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Evoke Pharma could also be used in its relative valuation, which is a method of valuing Evoke Pharma by comparing valuation metrics of similar companies.
Evoke Pharma is currently under evaluation in operating margin category among related companies.

Evoke Pharma Current Valuation Drivers

We derive many important indicators used in calculating different scores of Evoke Pharma from analyzing Evoke Pharma's financial statements. These drivers represent accounts that assess Evoke Pharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Evoke Pharma's important valuation drivers and their relationship over time.
201920202021202220232024 (projected)
Market Cap36.1M65.8M17.7M8.4M3.5M3.3M
Enterprise Value30.6M62.9M13.6M3.7M3.8M3.6M

Evoke Fundamentals

About Evoke Pharma Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Evoke Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Evoke Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Evoke Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Evoke Pharma using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
When determining whether Evoke Pharma is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Evoke Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Evoke Pharma Stock. Highlighted below are key reports to facilitate an investment decision about Evoke Pharma Stock:
Check out Evoke Pharma Piotroski F Score and Evoke Pharma Altman Z Score analysis.
For more information on how to buy Evoke Stock please use our How to buy in Evoke Stock guide.
You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Evoke Stock analysis

When running Evoke Pharma's price analysis, check to measure Evoke Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evoke Pharma is operating at the current time. Most of Evoke Pharma's value examination focuses on studying past and present price action to predict the probability of Evoke Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evoke Pharma's price. Additionally, you may evaluate how the addition of Evoke Pharma to your portfolios can decrease your overall portfolio volatility.
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Stocks Directory
Find actively traded stocks across global markets
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
CEOs Directory
Screen CEOs from public companies around the world
Is Evoke Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evoke Pharma. If investors know Evoke will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evoke Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.33)
Revenue Per Share
1.55
Quarterly Revenue Growth
1.105
Return On Assets
(0.49)
Return On Equity
(10.35)
The market value of Evoke Pharma is measured differently than its book value, which is the value of Evoke that is recorded on the company's balance sheet. Investors also form their own opinion of Evoke Pharma's value that differs from its market value or its book value, called intrinsic value, which is Evoke Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evoke Pharma's market value can be influenced by many factors that don't directly affect Evoke Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Evoke Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evoke Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evoke Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.